Sports Analysts Rate Spyre Therapeutics Stock as a Strong Buy Spyre Therapeutics, Inc. (NASDAQ:SYRE) has received a positive outlook from analysts, with an average recommendation of “Buy” from eleven research firms currently covering the... Editorial13 January, 2026